<DOC>
	<DOCNO>NCT02644655</DOCNO>
	<brief_summary>Objectives : The purpose study evaluate safety prognosis New Cluster Differentiation Antigen 19-chimeric Antigen Receptor T ( nCAR19-T ) Cells treatment recurrent/refractory B-cell tumor Optimal dosage nCAR19-T cell therapy . Methods : This study design novel therapy use nCAR19-T. 20 patient enrol . Cyclophosphamide 500 mg - 2000 mg/m2 ( day 2 ) without Fludarabine 30 mg/m2 /day , 4 day ( day-6 , -5 , -4 , -3 ) ; nCAR19-T transfusion：day 0 ( 5×10※5/kg，1×10※6/kg，3×10※6/kg ) . According National Cancer Institute ( NCI ) standard ( CTCAE ) , observe 24 week long . Follow-up survey clinical study : within 1 month , week ; month 1 year ; year , total 15 year .</brief_summary>
	<brief_title>Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor Treatment Recurrent /Refractory B Cell Leukemia</brief_title>
	<detailed_description>A total 20 patient may enrol period 1-2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Age ≥ 18 year old , male female 2 . Karnofsky≥60 % 3 . At least 2 course chemotherapy perform 4 . Creatinine le 2.5mg/dL ; alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) less 3 time normal bilirubin le 3mg/dL 5 . Adequate venous access , isolation , white blood cell production without taboos 6 . Signed informed consent 7 . Patients fertility willing use contraceptive method . 8 . At least two month infusion T cell 1 . Need use glucocorticoid therapy 2 . Need immunotherapy 3 . Creatinine ＞ 2.5mg/dL ; ALT / AST ＞ 5 time normal ; bilirubin ＞ 3mg/dL 4 . Forced expiratory volume one second ( FEV1 ) &lt; 2 L , diffuse capacity lung carbon monoxide ( DLCO ) ＜40 % 5. congestive cardiac failure ( III IV , NYHA ) ; Significant hypotension ; Coronary heart disease Can control ; DLCO＜40 % 6. human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) patient 7 . Had receive gene therapy 8 . Significant encephalopathy / new focal neurologic impairment 9 . Blood culture positive radiographic evidence infection 10 . Other drug , biological treatment , chemotherapy radiotherapy perform within month 11 . The history allergic reaction cell therapy cetuximab similar compound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Recurrent B-Cell Tumor</keyword>
	<keyword>Refractory B-Cell Tumor</keyword>
	<keyword>New Cluster Differentiation Antigen 19-chimeric Antigen Receptor T Cells</keyword>
	<keyword>safety</keyword>
	<keyword>prognosis</keyword>
</DOC>